A Comprehensive Clinical Evaluation of Desonide Cream in the Treatment of Eczematous Dermatoses
Expand
1.Graduate School of Bengbu Medical University， Anhui Bengbu 233000， China； 2.The First Affiliated Hospital of USTC Anhui Provincial Hospital， Anhui Hefei 230000， China
Objective： To establish a comprehensive clinical evaluation system for desonide cream in the treatment of eczema and dermatitis-like skin diseases， providing evidence-based support for drug policy formulation and clinical application. Methods： Based on the Health Technology Assessment (HTA) framework， evidence from pre-marketing and post-marketing stages was integrated across six dimensions： safety， efficacy， economy， innovation， suitability， and accessibility. Systematic searches of Chinese and English databases were conducted using evidence-based medicine evaluation methods， with R software employed for Meta-analysis. Cost-effectiveness analysis was applied to assess economic value， and clinical value was determined through horizontal comparison with similar drugs such as hydrocortisone. Results： Safety： Pre-marketing animal studies and Phase Ⅱ/Ⅲ clinical trials indicated no significant adverse effects to animals or human subjects. Post-marketing clinical studies demonstrated comparable safety and efficacy between desonide cream and hydrocortisone butyrate cream. Meta-analysis showed a lower incidence of adverse reactions with desonides (3.26%) than hydrocortisone (4.78%)， confirming its favorable safety profile. Efficacy： Pre-marketing pharmacodynamic studies revealed that desonide exhibits stronger activity than hydrocortisone and prednisolone. Phase Ⅱ/Ⅲ trials demonstrated considerable therapeutic effects， and post-marketing Meta-analysis indicated a higher total effective rate for desonide in treating eczema and dermatitis (RR=1.13 [1.05-1.22]) compared to hydrocortisone， confirming superior efficacy. Economy： Pharmacoeconomic analysis based on randomized controlled trials (RCT) showed that the incremental cost-effectiveness ratio (ICER) of desonide cream was below the per ca pita GDP. The additional cost for treating atopic dermatitis was fully justified， demonstrating cost-effectiveness advantages. The daily treatment cost was 0.7 CNY， with course expenses accounting for ≤0.1% of per ca pita disposable income， indicating high affordability. Innovation： Desonide cream is suitable for sensitive areas such as the facial skin of children， filling a clinical gap and exhibiting notable innovation value. Accessibility： The packaging complies with national standards， and the formulation， transportation， shelf life， indications， and administration are well-suited. Listed as a Class B medical insurance product with proportional reimbursement， desonide cream reducing patient financial burden. It is widely available across 31 provinces with sufficient supply， ensuring high accessibility. Conclusion： This study demonstrates that desonide cream exhibits a three-dimensional advantage of “high efficacy， low risk， and economic rationality” in treating eczema and dermatitis-like skin diseases， underscoring its significant clinical value.
